Clinical evidence for a role of E2F1-induced replication stress in modulating tumor mutational burden and immune microenvironment.
Cytosolic self-DNA
E2F1
Replication stress
Tumor immune microenvironment
Tumor mutational burden
Journal
DNA repair
ISSN: 1568-7856
Titre abrégé: DNA Repair (Amst)
Pays: Netherlands
ID NLM: 101139138
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
18
07
2022
revised:
05
06
2023
accepted:
28
06
2023
medline:
4
9
2023
pubmed:
16
7
2023
entrez:
15
7
2023
Statut:
ppublish
Résumé
DNA replication stress (RS) is frequently induced by oncogene activation and is believed to promote tumorigenesis. However, clinical evidence for the role of oncogene-induced RS in tumorigenesis remains scarce, and the mechanisms by which RS promotes cancer development remain incompletely understood. By performing a series of bioinformatic analyses on the oncogene E2F1, other RS-inducing factors, and replication fork processing factors in TCGA cancer database using previously established tools, we show that hyperactivity of E2F1 likely promotes the expression of several of these factors in virtually all types of cancer to induce RS and cytosolic self-DNA production. In addition, the expression of these factors positively correlates with that of ATR and Chk1 that govern the cellular response to RS, the tumor mutational load, and tumor infiltration of immune-suppressive CD4
Identifiants
pubmed: 37453246
pii: S1568-7864(23)00085-X
doi: 10.1016/j.dnarep.2023.103531
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
DNA
9007-49-2
E2F1 protein, human
0
E2F1 Transcription Factor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
103531Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM098535
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare no conflicts of interest.